Virgil Alain Silvester Hovestadt Dalm

Virgil Alain Silvester Hovestadt Dalm

Auto-generated profile, based on publicly available information

Virgil Alain Silvester Hovestadt Dalm

Department of Immunology, Erasmus MC University Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Clinical Immunology
Verified
Journal Article
Closed access
BJB.M. Jonkman-Berk
B.M. Jonkman-Berk
JBJ.M. van Den Berg
J.M. van Den Berg
IBI.J.M. Ten Berge
I.J.M. Ten Berge
RBR.G.M. Bredius
R.G.M. Bredius
GDG.J. Driessen
G.J. Driessen
TKTaco W. Kuijpers
Taco W. Kuijpers

11 April 2022 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
LLLeanne P.M. van Leeuwen
Leanne P.M. van Leeuwen
CGCorine H. GeurtsvanKessel
Corine H. GeurtsvanKessel
PEPauline M. Ellerbroek
Pauline M. Ellerbroek
GBGodelieve J. de Bree
Godelieve J. de Bree
JPJudith Potjewijd
Judith Potjewijd
VDVirgil A.S.H. Dalm
Virgil A.S.H. Dalm
Patients with inborn errors of immunity (IEI) are at increased risk of severe coronavirus disease-2019 (COVID-19). Effective vaccination against COVID-19 is therefore of great importance in this group, but little is known about the immunogenicity of COVID-19 vaccines in these patients. We sought to study humoral and cellular immune responses after mRNA-1273 COVID-19 vaccination in adult patients with IEI. In a prospective, controlled, multicenter study, 505 patients with IEI (common variable immunodeficiency [CVID], isolated or undefined antibody deficiencies, X-linked agammaglobulinemia, combined B- and T-cell immunodeficiency, phagocyte defects) and 192 controls were included. All participants received 2 doses of the mRNA-1273 COVID-19 vaccine. Levels of severe acute respiratory syndrome coronavirus-2–specific binding antibodies, neutralizing antibodies, and T-cell responses were assessed at baseline, 28 days after first vaccination, and 28 days after second vaccination. Seroconversion rates in patients with clinically mild antibody deficiencies and phagocyte defects were similar to those in healthy controls, but seroconversion rates in patients with more severe IEI, such as CVID and combined B- and T-cell immunodeficiency, were lower. Binding antibody titers correlated well to the presence of neutralizing antibodies. T-cell responses were comparable to those in controls in all IEI cohorts, with the exception of patients with CVID. The presence of noninfectious complications and the use of immunosuppressive drugs in patients with CVID were negatively correlated with the antibody response. COVID-19 vaccination with mRNA-1273 was immunogenic in mild antibody deficiencies and phagocyte defects and in most patients with combined B- and T-cell immunodeficiency and CVID. Lowest response was detected in patients with X-linked agammaglobulinemia and in patients with CVID with noninfectious complications. The assessment of longevity of immune responses in these vulnerable patient groups will guide decision making for additional vaccinations.

1 July 2018 in Journal of Autoimmunity
Verified
Journal Article
Closed access
IBIris L.A. Bodewes
Iris L.A. Bodewes
EHErika Huijser
Erika Huijser
CHCornelia G. van Helden-Meeuwsen
Cornelia G. van Helden-Meeuwsen
LTLiselotte Tas
Liselotte Tas
RHRuth Huizinga
Ruth Huizinga
MVMarjan A Versnel
Marjan A Versnel

10 September 2021 in Journal of Clinical Immunology
Verified
Journal Article
Open access
PDF file
SKSamer Raza Khan
Samer Raza Khan
LCLayal Chaker
Layal Chaker
MIMohammad Arfan Ikram
Mohammad Arfan Ikram
RPRobin Patrick Peeters
Robin Patrick Peeters
PHPetrus Martinus van Hagen
Petrus Martinus van Hagen
VDVirgil Alain Silvester Hovestadt Dalm
Virgil Alain Silvester Hovestadt Dalm
Purpose: In clinical practice, currently one reference range for serum immunoglobulin (Ig) A, G, and M is applied to all adults, although various factors may influence Ig serum levels. Population-based data on determinants of IgA, IgG, and IgM and recommendations for subgroup specific reference ranges are lacking. We aimed to provide an overview of determinants of IgA, IgG, and IgM in community-dwelling middle-aged and elderly individuals and explore determinants that influence Ig reference ranges. Methods: Within the Rotterdam Study, we performed linear regression analyses for the association of demographic, lifestyle, and cardiovascular factors with serum IgA, IgG, and IgM. We furthermore calculated Ig reference ranges (based on percentiles), both overall and within relevant subgroups. Results: We included 8768 participants (median age 62 years). IgA and IgG increased non-linearly with higher age (P < .0001 for both). Women had lower IgA (beta: − 0.24; 95% confidence interval [95% CI]: − 0.29; − 0.20) and IgG (beta: − 0.33; 95% CI: − 0.44; − 0.23), but higher IgM levels (beta: 0.08; 95% CI: 0.04;0.13) than men. Former and particularly current smoking were associated with lower IgA and IgG (betas between − 0.07 and − 1.03). Higher alcohol consumption was associated with lower IgG (beta for heavy drinking: − 0.70; 95% CI: − 0.91; − 0.48). Corticosteroid use was associated with lower IgG (beta: − 1.12; 95% CI: − 1.58; − 0.66). Associations with cardiovascular factors were heterogeneous and differed between sexes. Conclusion: Age, sex, smoking, alcohol consumption, corticosteroid use, and cardiovascular factors are determinants that should be considered when interpreting serum Ig levels in middle-aged and elderly individuals and may require adjusted reference ranges.

22 January 2019 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
KMKornvalee Meesilpavikkai
Kornvalee Meesilpavikkai
WDWillem A. Dik
Willem A. Dik
BSBenjamin Schrijver
Benjamin Schrijver
CHCornelia G. van Helden‐Meeuwsen
Cornelia G. van Helden‐Meeuwsen
MVMarjan A. Versnel
Marjan A. Versnel
VDVirgil A. S. H. Dalm
Virgil A. S. H. Dalm
Aicardi‐Goutières syndrome (AGS) is a rare early‐onset auto‐inflammatory disease characterized by basal ganglia calcification, chronic cerebrospinal fluid (CSF) lymphocytosis, and elevated type I interferon (IFN) levels in the CSF (1, 2). Typical clinical manifestations include developmental delay, intellectual impairment, chilblain, panniculitis, glaucoma, and autoimmunity overlapping with systemic lupus erythematosus (SLE)

6 March 2014 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
ZBZana Brkic
Zana Brkic
Odilia CornethOdilia Corneth
Odilia Corneth
CHCornelia G van Helden-Meeuwsen
Cornelia G van Helden-Meeuwsen
RDRadboud J.E.M. Dolhain
Radboud J.E.M. Dolhain
NMNaomi I Maria
Naomi I Maria
ELErik Lubberts
Erik Lubberts
Introduction: A hallmark of systemic autoimmune diseases like systemic lupus erythematosus (SLE) is the increased expression of interferon (IFN) type I inducible genes, so-called IFN type I signature. Recently, T-helper 17 subset (Th17 cells), which produces IL-17A, IL-17F, IL-21, and IL-22, has been implicated in SLE. As CCR6 enriches for Th17 cells, we used this approach to investigate whether CCR6+ memory T-helper cells producing IL-17A, IL-17F, IL-21, and/or IL-22 are increased in SLE patients and whether this increase is related to the presence of IFN type I signature. Methods: In total, 25 SLE patients and 15 healthy controls (HCs) were included. SLE patients were divided into IFN type I signature-positive (IFN+) (n = 16) and negative (IFN-) (n = 9) patients, as assessed by mRNA expression of IFN-inducible genes (IFIGs) in monocytes. Expression of IL-17A, IL-17F, IL-21, and IL-22 by CD4+CD45RO+CCR6+ T cells (CCR6+ cells) was measured with flow cytometry and compared between IFN+, IFN- patients and HCs. Results: Increased percentages of IL-17A and IL-17A/IL-17F double-producing CCR6+ cells were observed in IFN+ patients compared with IFN- patients and HCs. IL-17A and IL-17F expression within CCR6+ cells correlated significantly with IFIG expression. In addition, we found significant correlation between B-cell activating factor of the tumor necrosis family (BAFF)–a factor strongly correlating with IFN type I - and IL-21 producing CCR6+ cells. Conclusions: We show for the first time higher percentages of IL-17A and IL-17A/IL-17F double-producing CCR6+ memory T-helper cells in IFN+ SLE patients, supporting the hypothesis that IFN type I co-acts with Th17 cytokines in SLE pathogenesis.